Actively Recruiting
Evaluating CSL511 Fibrinogen Concentrate Versus Cryoprecipitate for Bleeding Control in Pseudomyxoma Peritonei During Cytoreductive Surgery with HIPEC
Led by CSL Behring · Updated on 2026-10-13
90
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of CSL511 fibrinogen concentrate compared to cryoprecipitate in adults with pseudomyxoma peritonei PMP undergoing cytoreductive surgery CRS combined with hyperthermic intraperitoneal chemotherapy HIPEC. This phase 3, randomized, open-label, controlled trial focuses on patients expected to have significant blood loss during surgery, aiming to improve hemostatic outcomes. Participants are randomly assigned to receive either the CSL511 fibrinogen concentrate or cryoprecipitate through intravenous infusion during surgery. The study assesses treatments during surgery and up to 24 hours afterward, focusing on blood clotting success. Secondary measures include adverse events monitoring for up to 30 days, blood loss, blood product requirements, surgery duration, and recovery parameters. Throughout the trial, participants undergo evaluations during surgery and postoperatively, including blood tests to monitor coagulation and fibrinogen levels up to 8 days after surgery. Researchers track the number of doses administered, blood loss, length of hospital and intensive care stays, reoperations, and mortality within 30 days. The primary outcome is the percentage of participants achieving overall hemostatic success from surgery through 24 hours post-surgery.
CONDITIONS
Brief Title
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Research Team
T
Trial Registration Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here